A St. Louis biotechnology company backed by $6 million in funding has relocated to a small space in one of the University of Maryland, Baltimore's research facilities.

KaloCyte joins as an affiliate of the university's BioPark, or biomedical research park, with the goal of bringing its synthetic red blood cell substitute to market. The product, called ErythroMer, is designed to take the place of blood in trauma situations or other times when it may be unavailable.

Read the full story from the Baltimore Business Journal.